Evidence map›Paper›PMID 19965540›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2010

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Rodrigo B Oliveira, Ana L E Cancela, Fabiana G Graciolli, Luciene M Dos Reis, Sérgio A Draibe, Lilian Cuppari, Aluizio B Carvalho, Vanda Jorgetti, Maria E Canziani, Rosa M A Moysés

2 registry-linked trialsOpen access · bronzeAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 177 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed, 5 pooled it
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01220843 phase3completednot on this map

Randomized Placebo Controlled Double-blind Trial in CKD Patients Not on Dialysis to Evaluate the Effect of Sevelamer Carbonate in the Control of FGF-23 Serum Levels and Its Consequences in the Evolution of PTH, Calcitriol and Mineral Metabolism Parameters Levels

TypeinterventionalSponsorCentre Hospitalier Universitaire, AmiensRan2010 to 2013Enrolled98ConditionsChronic Renal FailureArmsPlacebo, Sevelamer carbonate
NCT03550534 nacompletednot on this mapstarted 2015, after this paper: background citation

The Effectiveness and Safety of Calcium Carbonate in Chronic Kidney Disease With Normophosphatemia: A Double Blind, Randomized Controlled Trial

TypeinterventionalSponsorIndonesia UniversityRan2015 to 2016Enrolled46ConditionsChronic Kidney DiseasesArmsCalcium Carbonate, Placebo oral capsule
3 · Its place in the literature

Who cites it

177 citing papers in PubMed, 5 syntheses or guidelines pooled it, 352 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019
    Trial
  8. Trial
  9. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019
    Trial
  10. Trial
  11. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.Clinical journal of the American Society of Nephrology : CJASN · 2017
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.Clinical journal of the American Society of Nephrology : CJASN · 2014
    Trial
  19. Trial
  20. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2013
    Trial

117 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Rodrigo B OliveiraNephrology Department, Universidade de São Paulo, São Paulo, Brazil.
Ana L E Cancela
Fabiana G Graciolli
Luciene M Dos Reis
Sérgio A Draibe
Lilian Cuppari
Aluizio B Carvalho
Vanda Jorgetti
Maria E Canziani
Rosa M A Moysés
Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesLevels of parathyroid hormone (PTH) and the phosphaturic hormone FGF23, a fibroblast growth factor (FGF) family member, increase early in chronic kidney disease (CKD) before the occurrence of hyperphosphatemia. This short-term 6-wk dose titration study evaluated the effect of two phosphate binders on PTH and FGF23 levels in patients with CKD stages 3 to 4. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: Patients were randomized to receive over a 6-wk period either calcium acetate (n = 19) or sevelamer hydrochloride (n = 21).

resultsAt baseline, patients presented with elevated fractional excretion of phosphate, serum PTH, and FGF23. During treatment with both phosphate binders there was a progressive decline in serum PTH and urinary phosphate, but no change in serum calcium or serum phosphate. Significant changes were observed for FGF23 only in sevelamer-treated patients.

conclusionsThis study confirms the positive effects of early prescription of phosphate binders on PTH control. Prospective and long-term studies are necessary to confirm the effects of sevelamer on serum FGF23 and the benefits of this decrease on outcomes.

Indexed as

AcetatesAdultBiomarkersBone Diseases, MetabolicCalcium CompoundsChelating AgentsChronic DiseaseFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansHyperparathyroidism, SecondaryKidney DiseasesMaleMiddle AgedParathyroid HormoneAcetatesBiomarkerscalcium acetateCalcium CompoundsChelating AgentsFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsParathyroid HormonePhosphatesPolyaminesPTH protein, humanSevelamer

Identifiers

PMID19965540
PMCPMC2827593
OpenAlexW2138484848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.